Effect of zoledronate on the osteoclast adhesion and gene expression of integrinαv andβ3
10.7518/hxkq.2014.06.004
- VernacularTitle:唑来膦酸对破骨细胞黏附及整合素αv、β3基因表达的影响
- Author:
Jueshan LIN
1
;
Wei DONG
;
Chunfeng XU
;
Hong SUN
;
Xiaojie FENG
;
Mengchun QI
Author Information
1. 河北联合大学口腔医学院口腔颌面外科教研室
- Keywords:
zoledronate;
osteoclast;
cell adhesion;
integrin αv and β3;
sealing zone
- From:
West China Journal of Stomatology
2014;(6):547-551
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of zoledronate (ZOL) on the osteoclast adhesion and expression of integrin αv and β3 in vitro. Methods Mice RAW264.7 cells were used for osteoclast differentiation in vitro, and osteoclastogenesis was examined by tartrate-resistant acid phosphatase (TRAP) staining and dentin resorption lacunae examination. The cells were then divided into 2 groups, the control group and ZOL treatment group (treated with 1×10-6 mol·L-1 ZOL for 2 d). The adhesion ability of osteoclasts and mRNA and the protein expressions of integrin αv and β3 were examined by crystal violet staining, real-time fluorescence quantitative polymerase chain reaction, Western blot analysis, and immunofluorescent chemistry. Results TRAP staining and dentin resorption lacunae examination revealed the formation of multi-nuclear osteoclasts. ZOL treatment significantly decreased the adhesion ability of osteoclasts (P<0.01). In the ZOL-treated group, the mRNA levels of integrin αv and β3 were 0.66±0.05 and 0.59±0.08, respectively. In the control group, the mRNA levels of integrin αv and β3 were 1.01±0.01 and 1.01±0.02, respectively; these values were higher than those in the ZOL-treated group (P<0.01). The protein level of integrin αv and β3 in the ZOL-treated group (31 934.84±112.91 and 18 812.79±194.13) was downregulated by approximately 39.19% and 40.17%, respectively, compared with those in the control group (52 517.81± 211.72 and 31 441.93±456.87) (P<0.01). Immunofluorescent examination showed that the fluorescent intensities of integrin αv and β3 in the ZOL-treated group (9.491±0.748 and 4.744±0.759) were also significantly decreased compared with those in the control group (15.159±1.143 and 11.418±1.095) (P< 0.01). Conclusion ZOL significantly inhibits osteoclast adhesion and downregulates integrin αv and β3 expression, thus contributing to the ZOL-induced inhibition of osteoclastmediated bone resorption.
